Angela Bacca has been covering the cannabis industry for over 15 years. She has authored hundreds of articles, edited and/or co-authored nearly a dozen books, and edited various online and print cannabis-centric publications. She has focused on cannabis economics, politics, science, horticulture, cultural issues, non-cannabis herbalism, and complementary and alternative health topics.
Metro Vancouver is considering potential revisions to their plan to manage emissions from cannabis growers.
The revisions, presented in a staff report on July 6, include allowing for more flexibility for the type of required emission control technology in cannabis greenhouses, and encouraging municipalities to set minimum distances between new facilities and neighbouring land uses.
Metro Vancouver—which encompasses 21 cities in BC’s Lower Mainland, one electoral area, and one treaty First Nation—first announced its plans to regulate volatile organic compounds (VOCs) from cannabis production in 2019, holding stakeholder meetings in late 2020 and early 2021.
The first phase of engagement from Metro Vancouver for the new potential cannabis production and processing regulation ended in November 2019. This was followed by a second phase of engagement from August 2021 to February 2022. The newest staff report provided feedback from that engagement process, including various federal, provincial, municipal, and First Nations agencies, the general public, and the cannabis industry.
This feedback included support for efforts to regulate VOCs, along with concerns around municipal jurisdiction, concern that the proposed regulations could impact smaller producers and give advantages to the illicit market which would face no such restrictions, and that Metro Vancouver shouldn’t be regulating cannabis sector emissions because it’s an agricultural activity.
The report also notes that in 2021, the BC Ministry of Agriculture, Food and Fisheries issued a report that called into question Metro Vancouver’s plans, arguing that cannabis production only accounts for a small fraction of overall VOCs in the region.
It estimated that indoor cannabis accounts for about 146 tonnes of VOCs per year, compared to 715 for crops and pasture land, 9,500 from plants and vegetation (non-commercial crops), and over 37,000 for other non-agricultural human sources such as fuel, vehicles, and paints and chemical products.
A representative for the Cannabis Cultivators of British Columbia (CCBC), which has been pushing back against Metro Van’s efforts, told StratCann they see the proposed approach to be based in an anti cannabis bias, rather than legitimate environmental concerns.
“We have serious concerns about how staff at Metro Vancouver are advancing regulations against cannabis growers in the region, which are rooted in stigma not science. Proposed regulations are predicated on measures that are inconsistent, remain untested, and are not scientifically validated. In fact, over the past year scientific evidence has emerged that contradicts some of the base assumptions being made by Metro Vancouver. Furthermore, Metro Vancouver is using incorrect calculations, projecting growth when in reality cannabis production in the region has experienced marked decline over the past two years.
“These regulations single out legal cannabis growers only and put at risk an already struggling agricultural sector that supports the employment of thousands of people and generates positive economic impacts across the province.”
Metro Vancouver’s staff report says the feedback is being used to help finalize the proposed regulation for the committee and board’s consideration in 2023.
Staff recommended that the the Metro Vancouver Regional District Board (MVRD):
a) send a letter to the Ministers of Agriculture and Food, Environment and Climate Change Strategy, and Public Safety and the Solicitor General requesting collaboration with Metro Vancouver on developing a concerted approach for managing emissions from cannabis production and processing in the Metro Vancouver region in a manner that protects public health and regional economic prosperity;
b) and direct staff to continue developing options to manage emissions from cannabis production and processing as described in the report dated June 23, 2023, titled “Phase 2 Engagement Summary and Next Steps for Managing Emissions from Cannabis Production and Processing.”
The item will go to the Board next for consideration. The next board meeting is schedule for Friday, July 28.
Health Canada declined to provide the number of licensed cannabis cultivators in the Lower Mainland, citing “piracy concerns.”
With over twenty years of product development, brand-building and consumer marketing experience serving American Express, MasterCard, PepsiCo and Microsoft–and over ten years in the legal cannabis space at Dope Magazine and as a consultant to the industry’s top national manufacturers, Paleschuck has played a part in developing many of today’s best-known cannabis brands.
As Founder of PALESCHUCK, LLC, David consults within the legal cannabis industry on product development, branding & brand licensing, positioning, packaging and promotions. His writings on cannabis branding and marketing have been featured in Dope Magazine, High Times, MG, PROHBTD, High Times, Celebstoner, Cannabis Dispensary Magazine, The Cannabis Industry Journal, New Cannabis Ventures, among others. His work has been noted and quoted in Forbes, Kiplingers, The Brookings Institution as well as interviewed by Wharton School Of Business Entrepreneur Radio; CannabisRadio; among others.
David’s book, “Branding Bud: The Commercialization of Cannabis” – the first book on cannabis branding – released in April 2021 and ramped to be the best-selling book on Amazon in the “Branding & Logo Design” and “Green Business” categories. As Founder of the Branding Bud Consulting Group, he now consults on many aspects of legal cannabis to those both currently in the industry and to those wanting to enter it.
Bipartisan congressional legislators are pleased with recent actions by the U.S. Food and Drug Administration (FDA) regarding psychedelic policy and research. Only a few days after the lawmakers filed a bill requesting that the agency craft measures to guide psychedelic research in the United States, the FDA published the country’s first draft guidance on psychedelic research.
Released in late June, the draft stated that psychedelics showed “initial promise” as potential therapies and outlined “unique” considerations for researchers to note during their research. The 14-page document provides America’s first-ever framework for psychedelic research and could aid in the eventual development of psychedelic-based treatments.
Representative Dan Crenshaw, who introduced the bill asking for guidance on psychedelic research alongside Representatives Ro Khanna and Mariannette Miller-Meeks said that he is glad the regulatory agency decided to publish guidance for clinical trials on psychedelics. He added that it was important for legislators and regulators to create a framework that allowed researchers to keep on studying psychedelics.
A military veteran, Crenshaw explained that the guidance should increase access to psychedelic clinical trials to ensure that active service members, veterans and people living with conditions such as substance abuse disorder, traumatic brain injuries and post-traumatic stress disorder (PTSD) can access psychedelic treatments.
Psychedelics have captured the attention of lawmakers such as Crenshaw and millions of other Americans due to their purported mental health benefits. A growing body of literature and anecdotal reports show that psychedelics can deliver profound mental-health benefits even where traditional psychiatric medications have failed. Hallucinogens such as psilocybin, MDMA and LSD have been found to offer long-term relief against various mental health disorders at minimal doses and with few, if any, side effects.
Miller-Meeks said that many veterans are already using guided psychedelic therapy to treat “excruciating, post-traumatic pain” with fewer side effects and better outcomes in pilot studies. She said that she knew the value of medical research because of her medical background, and she was encouraged by the FDA’s decision to issue guidance on psychedelic research and clinical trials.
Shortly after issuing the guidance, the FDA published a notice in the Federal Register and launched a 60-day comment period for the public to discuss the proposed guidance and offer opinions on how the final guidance should look.
Director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research Tiffany Farchione said that psychedelics are still “investigational products” and advised sponsors to “consider their unique characteristics” while designing psychedelic clinical studies.
Leading startups such as Compass Pathways PLC (NASDAQ: CMPS) are undoubtedly assessing the new guidelines to see whether many of their concerns are addressed. The feedback that the federal agency receives could reflect any concerns these companies have about the draft guidance.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its mid-year update, marking significant strides both in its research and in creating value for its shareholders. In a report by Zacks Small Cap Research, the company’s critical milestones for the current calendar year were highlighted, from recent publications to awarded patents and capital raised thus far.
Of note was Lexaria’s most ambitious clinical study yet, HYPER-H21-4, a clinical study exploring the potential of the company’s patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of hypertension. Enrollments for the study kicked off in April 2022, with dosing beginning ahead of schedule and completed on July 27th (https://cnw.fm/1HQdu). With the success of this study so far, Lexaria is on track to file an Investigational New Drug application with the U.S. Food and Drug Administration, for DehydraTECH-processed CBD later this year, in addition to tapping into the hypertension treatment market that is estimated to hit $39.5 billion in value by 2030 (https://cnw.fm/zNTt1).
Lexaria has also made significant strides in growing its patent portfolio, with its 28th patent worldwide being awarded in late December 2022. Two additional announcements were made in April and June highlighting several global grants, in addition to six patents awarded across Australia, Japan, the United States, and Canada so far in 2023. This goes a long way in strengthening the Lexaria brand, as evidenced by the $2 million capital raise on May 8th.
This capital raise in a public offering saw 2,106,000 units sold at $0.95 per unit, consisting of one share of stock and a warrant with an exercise price of $0.95 per share, offering a five-year term. It showed shareholders’ confidence in the company and its efforts to grow its operations and fulfill its mandate. It was also a show of the company’s growth and future ambitions.
Lexaria also noted significant progress on its nicotine operations, particularly given its receipt of Independent Review Board (“IRB”) approval for its human nicotine study designated NIC-H22-1. Similar progress was made on its Estradiol hormone study, with the recently-concluded animal study HOR-A22-1 demonstrating successful delivery of estradiol and its metabolite estrone using DehydraTECH. These, and more efforts from Lexaria, were recognized in research circles, with eight research paper publications playing a massive role in it.
In a June 22nd press release, Lexaria acknowledged its most recent publication in the International Journal of Molecular Sciences, titled Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study. The publication noted that CBD concentrations were higher in women than men and correlated with the proportion of adipose tissue. The difference in sexes, it noted, was attributed to higher levels of fat tissue in women than men.
Lexaria looks to build on its momentum so far and achieve its objectives for the 2023 calendar year. Its management is optimistic that these goals, and more, will be achieved in the year and that the company will continue to create value for its shareholders while at it.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cannabisnewswire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
MISSISSIPPI (July 11, 2023) — As medical cannabis dispensaries open for the first time across the state of Mississippi, Oaksterdam University (OU) is excited to offer Mississippi Medical Cannabis Dispensary Worker Training. The self-paced online training is approved by the Mississippi State Department of Revenue and meets all requirements to certify medical cannabis dispensary workers.
The course provides the most comprehensive education for pursuing a medical cannabis dispensary worker career in the $27 billion global cannabis industry. Individuals who finish the course may download a verifiable certificate of completion that qualifies them to work in a state-licensed dispensary.
Oaksterdam University is the world’s first cannabis college and is the most trusted provider of training in the industry with curriculum developed by expert faculty who are leaders in the burgeoning cannabis space. OU’s Mississippi Medical Cannabis Dispensary Worker Training prepares dispensary workers to be safe, informed, and compliant with state regulations. It includes:
The training program and certification are $49.99, with group discounts available, making it the least expensive and most comprehenisve state-approved option for individuals and dispensary teams alike. It is accessible online – anytime, from anywhere – at the student’s own pace.
— Patients must be diagnosed with one of the qualifying conditions listed in the Mississippi Medical Cannabis Act to qualify for a medical cannabis patient registration card. Conditions include cancer, Parkinson’s, Huntington’s, muscular dystrophy, Crohn’s, Alzheimer’s, severe injury, chronic pain and more.
— Patients must be certified by a medical doctor, doctor of osteopathy, certified nurse practitioner, physician assistant, or optometrist licensed to prescribe medicine in Mississippi.
— In Mississippi, cannabis flower is capped at a total THC potency of 30 percent. Cannabis products are capped at a total THC potency of 60 percent.
— Apothecary or “deli-style” loose cannabis is not allowed for sale at Mississippi Medical Dispensaries.
These and many other Mississippi-specific laws and regulations are included in Oaksterdam’s Mississippi Medical Cannabis Dispensary Worker Training. For more information or to set up an interview with an Oaksterdam expert, email OU Communication Specialist Wensdy Von Buskirk at [email protected]
About Oaksterdam
Oaksterdam University has been the forerunner in providing the highest quality training to people involved in the cannabis industry since 2009. OU’s faculty is composed of professionals, academics, and subject matter experts who have taught more than 80,000 OU alumni from 110 countries. With roots growing 27 years deep, OU is a dynamic, diverse, and responsive academic institute dedicated to educating the global cannabis community, industry, regulators, and government. Visit OaksterdamUniversity.com
Official Course Textbook
The official optional textbook for Mississippi Medical Cannabis Dispensary Training is The Budtender’s Guide: A Reference Manual for Cannabis Consumers and Dispensary Professionals. Published by Oaksterdam Press, this powerful resource complements the course material and serves as a comprehensive guide to cannabis use, products and effects. It is available as an e-book ($9.99) or in print ($29.99).
Two months after Maryland approved legislation to create a regulatory framework for recreational cannabis sales, the state has officially launched its adult-use market. State lawmakers approved Senate Bill 516 in April following months of negotiation on key issues such as social equity and taxation before forwarding it to the governor’s desk.
Governor Wes Moore signed the measure into law in May and set the stage for recreational sales in Maryland, stating at the time that the bill would make sure Maryland’s recreational cannabis market would provide equitable opportunity. The recreational cannabis bill finally took effect last week and made simple possession and personal cultivation of cannabis legal. It will also allow existing medical cannabis dispensaries to begin selling adult-use marijuana, ensuring that the state’s recreational market will see a relatively quick launch just months after legalization.
Regulators have already approved close to 100 dispensaries and converted their medical cannabis licenses to dual licenses that will allow businesses to serve both medical cannabis patients and adult consumers from July 1, 2023. The Maryland Cannabis Administration (MCA) has also approved 38 recreational cannabis cultivators and manufacturers to help supply the burgeoning market.
Cannabis is without a doubt one of the fastest-growing industries in the world. The industry has created hundreds of thousands of new job opportunities and generated billions of dollars in annual taxes, with states such as California regularly reporting hundreds of millions of dollars in cannabis taxes per year.
Most states with legal cannabis markets have also included social equity provisions that ensure members of communities that were disproportionately affected by the failed war on drugs have equitable access to the lucrative cannabis market.
Speaking at a recent Cannabis Regulators Association (CANRA) conference, Governor Moore noted that cannabis policy has been used to oppress people of color in the past and weakened not just certain communities but the country as a whole. He said that the state was now penning a new chapter in America’s sordid tale with cannabis, a chapter focused on ensuring both equity and economic growth.
Acting MCA Director Will Tilburg said that the association is excited to “offer safe, legal and tested” cannabis products to adults, and urged consumers to learn about the recreational cannabis law and practice safe, responsible cannabis consumption.
Customers can now purchase pre-rolled joints, dried cannabis flower, disposable vape pens, vape cartridges, capsules, topical products and edibles with no more than 10mg of THC per serving and 100 mg of THC per package.
Smoking in public spaces, restaurants and moving cars is not allowed, and it is still illegal to drive while under the influence of marijuana or transport cannabis products out of the state of Maryland.
As more U.S. states start implementing recreational cannabis programs, several enterprises such as IGC Pharma Inc. (NYSE American: IGC) are also working to raise the bar for the medical use of marijuana by developing formulations that meet the requirements of regulators such as the FDA before such formulations are licensed for use within the healthcare system.
NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
Recent Comments